Text Size

Ketamine Anesthesia in Electroconvulsive Therapy

This study has been completed.
Sponsor:
Information provided by:
Mayo Clinic
ClinicalTrials.gov Identifier:
NCT01367119
First received: June 1, 2011
Last updated: November 7, 2012
Last verified: November 2012
History of Changes
  Purpose

Does the use of ketamine as the anesthetic medication in electroconvulsive therapy (ECT) accelerate the antidepressant effect of ECT?


Condition Intervention
Depression
 Drug: Ketamine
Drug: methohexital

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized Comparison of Ketamine and Methohexital Anesthesia for ECT in Depression

Resource links provided by NLM:

MedlinePlus related topics: Anxiety Depression
U.S. FDA Resources

Further study details as provided by Mayo Clinic:

Primary Outcome Measures:
  • depression ratings using the Hospital Anxiety and Depression Scale [ Time Frame: Baseline and after every second treatment for 20 mins. ] [ Designated as safety issue: No ]
    Patients will be followed with these outcome measures as long as they are still receiving inpatient ECT treatments. The number of treatments will be determined entirely by their primary psychiatric team, also blind to anesthetic, as per usual care. In other words, this study will not be determining when to terminate the ECT course.


Enrollment: 40
Study Start Date: May 2011
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: ketamine anesthesia
using ketamine as the anesthetic agent
 Drug: Ketamine
using ketamine as anesthetic
Active Comparator: methohexital
using methohexital as anesthetic
 Drug: methohexital
using methohexital as anesthetic

Detailed Description:

To compare outcomes with electroconvulsive therapy using ketamine or methohexital as anesthetic.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria:

  • patients receiving ECT at the Mayo Clinic

Exclusion criteria:

  • patients not giving their own consent to ECT
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01367119

Locations
United States, Minnesota
Mayo Clinic in Rochester
Rochester, Minnesota, United States, 55905
Sponsors and Collaborators
Mayo Clinic
Investigators
Principal Investigator: Keith Rasmussen, MD Mayo Clinic
  More Information

No publications provided

Responsible Party: Keith Rasmussen, MD, Mayo Clinic
ClinicalTrials.gov Identifier: NCT01367119     History of Changes
Other Study ID Numbers: 11-001430
Study First Received: June 1, 2011
Last Updated: November 7, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Anesthetics
Ketamine
Methohexital
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
 Therapeutic Uses
Anesthetics, Dissociative
Anesthetics, Intravenous
Anesthetics, General
Excitatory Amino Acid Antagonists
Excitatory Amino Acid Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on May 22, 2013